|[January 31, 2014]
Exelixis Announces Webcasts of Investor Conference Presentations in February
SOUTH SAN FRANCISCO, Calif. --(Business Wire)--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company's president and chief executive officer, will present
at the following two investor conferences in February:
Biotechnology Industry Organization CEO & Investor Conference:
Exelixis' presentation is scheduled for 8:30 a.m. EST / 5:30 a.m. PST
on Tuesday, February 11, 2014 in New York.
Leerink Swann Global Healthcare Conference: Exelixis' presentation is
scheduled for 11:30 a.m. EST / 8:30 a.m. PST on Wednesday, February
12, 2014 in New York.
During each presentation, Dr. Morrissey will review the company's
development plans and priorities for cabozantinib in 2014. He will also
discuss the company's corporate strategy and financial outlook, and
provide a general business update.
Each presentation will be webcast and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ®
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.
[ Back To TMCnet.com's Homepage ]